# Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

> **NCT00003225** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003225
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** 2000-03
- **Final completion:** 2001-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003225, "Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*